Lydia Anette Schoenpflug

Lydia Anette Schoenpflug

Auto-generated profile, based on publicly available information

Lydia Anette Schoenpflug

Department of Biomedical Engineering, University of Basel, Allschwil, Switzerland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2024 in The Journal of Pathology
Verified
Journal Article
Open access
LSLydia A Schoenpflug
Lydia A Schoenpflug
ACAikaterini Chatzipli
Aikaterini Chatzipli
KSKorsuk Sirinukunwattana
Korsuk Sirinukunwattana
SRSusan Richman
Susan Richman
ABAndrew Blake
Andrew Blake
VKViktor H Koelzer
Viktor H Koelzer
Tumour content plays a pivotal role in directing the bioinformatic analysis of molecular profiles such as copy number variation (CNV). In clinical application, tumour purity estimation (TPE) is achieved either through visual pathological review [conventional pathology (CP)] or the deconvolution of molecular data. While CP provides a direct measurement, it demonstrates modest reproducibility and lacks standardisation. Conversely, deconvolution methods offer an indirect assessment with uncertain accuracy, underscoring the necessity for innovative approaches. SoftCTM is an open‐source, multiorgan deep‐learning (DL) model for the detection of tumour and non‐tumour cells in H&E‐stained slides, developed within the Overlapped Cell on Tissue Dataset for Histopathology (OCELOT) Challenge 2023. Here, using three large multicentre colorectal cancer (CRC) cohorts ( N = 1,097 patients) with digital pathology and multi‐omic data, we compare the utility and accuracy of TPE with SoftCTM versus CP and bioinformatic deconvolution methods (RNA expression, DNA methylation) for downstream molecular analysis, including CNV profiling. SoftCTM showed technical repeatability when applied twice on the same slide ( r = 1.0) and excellent correlations in paired H&E slides ( r > 0.9). TPEs profiled by SoftCTM correlated highly with RNA expression ( r = 0.59) and DNA methylation ( r = 0.40), while TPEs by CP showed a lower correlation with RNA expression ( r = 0.41) and DNA methylation ( r = 0.29). We show that CP and deconvolution methods respectively underestimate and overestimate tumour content compared to SoftCTM, resulting in 6–13% differing CNV calls. In summary, TPE with SoftCTM enables reproducibility, automation, and standardisation at single‐cell resolution. SoftCTM estimates ( M = 58.9%, SD ±16.3%) reconcile the overestimation by molecular data extrapolation (RNA expression: M = 79.2%, SD ±10.5, DNA methylation: M = 62.7%, SD ±11.8%) and underestimation by CP ( M = 35.9%, SD ±13.1%), providing a more reliable middle ground. A fully integrated computational pathology solution could therefore be used to improve downstream molecular analyses for research and clinics. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.


9 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NBNikki van Den Berg
Nikki van Den Berg
LSLydia Schoenpflug
Lydia Schoenpflug
NHNanda Horeweg
Nanda Horeweg
SVSarah Volinsky-Fremond
Sarah Volinsky-Fremond
JBJurriaan Barkey-Wolf
Jurriaan Barkey-Wolf
TBTjalling Bosse
Tjalling Bosse
POLE sequencing for somatic mutations ( POLE mut) guides adjuvant therapy in endometrial cancer (EC), but cost and infrastructural considerations lead to limited uptake. Omission of POLE testing leads to unnecessary exposure to radiotherapy and/or chemotherapy. We developed POLARIX, a multiple instance deep learning model with attention pooling, which predicts POLE mutation status from routine hematoxylin and eosin whole-slide images (WSIs). Trained on 2,238 cases from eleven EC cohorts, POLARIX showed clinical-grade discrimination across three external cohorts (Pooled: AUC=0.95, 95% CI: 0.91–0.98; n =68/481 POLE mut/ POLE wt). Attention maps highlight POLE morphologies. Clinical applicability is demonstrated using predefined thresholds based on three resource scenarios. The most sensitive threshold (“Low”) yields a test reduction of 77% (73%-81%) (sensitivity: 93% (85%-99%), specificity: 89% (87%-92%)). POLARIX is an interpretable and cost-efficient approach to reduce POLE testing in women with endometrial cancer, broadening access to precision oncology.

20 October 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LSLydia A. Schoenpflug
Lydia A. Schoenpflug
NBNikki J. van Den Berg
Nikki J. van Den Berg
SCSerey Vathana Chhut
Serey Vathana Chhut
ELElaine Leung
Elaine Leung
Lai Meng LooiLai Meng Looi
Lai Meng Looi
NHNanda Horeweg
Nanda Horeweg
Introduction: Cancer incidence is rising rapidly in low- and middle-income countries (LMICs), where diagnostic pathology capacity is constrained. AI applied to routine histopathology could strengthen diagnostic capacity and offer leapfrogging potential by embedding AI into diagnostic systems as they are built up. However, without empirically identifying implementation determinants in LMIC cancer-diagnostic settings, AI solutions risk being poorly aligned with local constraints, limiting impact or exacerbating existing disparities. Methods: We conducted an exploratory mixed-methods pilot study across three phases: 1) a structured survey characterising the diagnostic and technical landscape and AI priorities; 2) focus group discussions (FGDs) to inductively identify implementation determinants and 3) a second survey quantifying FGD-derived themes. Twelve physicians were purposively recruited (10 from LMIC, 2 from high-income countries for reference) and findings integrated through narrative triangulation. Results: There was substantial heterogeneity in diagnostic and AI infrastructure that did not track consistently with country income classification. H&E staining was universally available, immunohistochemistry capacity was rudimentary at 7 of 10 sites and molecular testing absent or minimal at 6 of 10 sites. Whole-slide-imaging scanners were available at 8 of 10 sites, while graphical processing units, required for efficient AI inference, were available at only 4 of 10 sites. The participants would prioritise use of AI for cancer screening, cancer diagnosis, and biomarker prediction from H&E slides. Six implementation determinants were identified: AI literacy, governance frameworks, funding, evidence generation, clinical deployment, and collaboration. Financial constraints emerged as the dominant barrier across all determinants, and collaboration as an important enabling mechanism. Conclusion: AI implementation readiness in LMIC cancer-diagnostic settings is highly heterogeneous and cannot be inferred from income classification, underscoring the need for institution-level assessment. Realising the leapfrogging potential of AI in this context requires coordinated progress across all determinants, with sustainable financing, and collaboration enabling the remaining determinants. Key messages: What is already known on this topic?: Cancer incidence is rising rapidly in LMICs, where diagnostic capacity and molecular testing capabilities are severely constrained. AI could alleviate gaps, yet evidence on implementation determinants for integrating AI into cancer diagnostics in these settings remains limited. What this study adds?: AI implementation readiness varies substantially within LMIC settings and does not track with country income classification. Readiness is shaped by six implementation determinants: AI literacy, governance frameworks, funding, evidence generation, clinical deployment, and collaboration, with financial constraints as the dominant cross-cutting barrier. How this study might affect research, practice or policy?: These findings support institution-level feasibility assessment over income-classification proxies and highlight the need for sustainable financing and collaboration as foundational prerequisites for AI implementation in cancer diagnostics in LMICs.

19 December 2023 in arXiv
Verified
Preprint
Open access
PDF file
LSLydia A. Schoenpflug
Lydia A. Schoenpflug
VKViktor H. Koelzer
Viktor H. Koelzer
Detecting and classifying cells in histopathology H\&E stained whole-slide images is a core task in computational pathology, as it provides valuable insight into the tumor microenvironment. In this work we investigate the impact of ground truth formats on the models performance. Additionally, cell-tissue interactions are considered by providing tissue segmentation predictions as input to the cell detection model. We find that a "soft", probability-map instance segmentation ground truth leads to best model performance. Combined with cell-tissue interaction and test-time augmentation our Soft Cell-Tissue-Model (SoftCTM) achieves 0.7172 mean F1-Score on the Overlapped Cell On Tissue (OCELOT) test set, achieving the third best overall score in the OCELOT 2023 Challenge. The source code for our approach is made publicly available at https://github.com/lely475/ocelot23algo.